BR112012020311A2 - "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." - Google Patents

"compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto."

Info

Publication number
BR112012020311A2
BR112012020311A2 BR112012020311A BR112012020311A BR112012020311A2 BR 112012020311 A2 BR112012020311 A2 BR 112012020311A2 BR 112012020311 A BR112012020311 A BR 112012020311A BR 112012020311 A BR112012020311 A BR 112012020311A BR 112012020311 A2 BR112012020311 A2 BR 112012020311A2
Authority
BR
Brazil
Prior art keywords
compound
cancer
treatment
prophylaxis
inhibiting
Prior art date
Application number
BR112012020311A
Other languages
English (en)
Other versions
BR112012020311B1 (pt
Inventor
Homma Misaki
Kurasawa Osamu
Miyazaki Toru
Oguro Yuya
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012020311(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112012020311A2 publication Critical patent/BR112012020311A2/pt
Publication of BR112012020311B1 publication Critical patent/BR112012020311B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Abstract

compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto. é divulgado um composto útil como um agente profilático ou terapêutico para o câncer. é especificamente divulgado um composto representado pela fórmula (i). [em que cada símbolo é como definido na descrição] ou um sal deste, ou um pró-medicamento do composto ou sal deste, que é útil para a prevenção ou tratamento de câncer.
BR112012020311-8A 2010-02-17 2011-02-16 composto heterocíclico fundido tendo uma atividade inibidora de ciclo 7 de divisão celular forte (cdc7), e, medicamento compreendendo o mesmo BR112012020311B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010-031899 2010-02-17
JP2010-131950 2010-06-09
JP2010131950 2010-06-09
PCT/JP2011/053303 WO2011102399A1 (ja) 2010-02-17 2011-02-16 複素環化合物

Publications (2)

Publication Number Publication Date
BR112012020311A2 true BR112012020311A2 (pt) 2017-03-01
BR112012020311B1 BR112012020311B1 (pt) 2019-01-29

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020311-8A BR112012020311B1 (pt) 2010-02-17 2011-02-16 composto heterocíclico fundido tendo uma atividade inibidora de ciclo 7 de divisão celular forte (cdc7), e, medicamento compreendendo o mesmo

Country Status (35)

Country Link
US (6) US8722660B2 (pt)
EP (2) EP3533797B1 (pt)
JP (1) JP5689454B2 (pt)
KR (1) KR101735868B1 (pt)
CN (1) CN102844320B (pt)
AU (1) AU2011216404B2 (pt)
BR (1) BR112012020311B1 (pt)
CA (1) CA2790284C (pt)
CL (1) CL2012002250A1 (pt)
CO (1) CO6592104A2 (pt)
CR (1) CR20120448A (pt)
CY (1) CY1121792T1 (pt)
DK (1) DK2540728T3 (pt)
DO (1) DOP2012000224A (pt)
EA (1) EA020724B1 (pt)
EC (1) ECSP12012160A (pt)
ES (1) ES2733221T3 (pt)
GE (1) GEP20146202B (pt)
HR (1) HRP20190947T1 (pt)
HU (1) HUE043514T2 (pt)
IL (1) IL221442A0 (pt)
LT (1) LT2540728T (pt)
MA (1) MA34064B1 (pt)
ME (1) ME03410B (pt)
MX (1) MX353500B (pt)
MY (1) MY164776A (pt)
NZ (1) NZ602089A (pt)
PE (1) PE20130184A1 (pt)
PL (1) PL2540728T3 (pt)
PT (1) PT2540728T (pt)
RS (1) RS58796B1 (pt)
SG (1) SG183304A1 (pt)
SI (1) SI2540728T1 (pt)
TN (1) TN2012000401A1 (pt)
WO (1) WO2011102399A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20131304A1 (es) * 2010-08-11 2013-11-14 Millennium Pharm Inc Heteroarilos y sus usos
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
KR102006320B1 (ko) 2015-12-07 2019-08-02 지머젠 인코포레이티드 Htp 게놈 공학 플랫폼에 의한 미생물 균주 개량
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
PT3436463T (pt) * 2016-03-28 2021-09-06 Takeda Pharmaceuticals Co Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
US11020396B2 (en) 2016-11-08 2021-06-01 Cancer Research Technology Limited Pyrimidinone derivatives as Cdc7 inhibitors
US11155879B2 (en) * 2017-03-01 2021-10-26 Takeda Pharmaceutical Company Limited Method of predicting effects of CDC7 inhibitor
CN110381950B (zh) * 2017-05-21 2020-09-04 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
CA3095264A1 (en) * 2018-04-02 2019-10-10 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TW202016316A (zh) 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
CA3106557A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
SG11202113212YA (en) * 2019-05-30 2021-12-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tetracyclic compounds as cdc7 inhibitors
CA3146792A1 (en) * 2019-07-19 2021-01-28 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schroedinger Inc CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
CN116490507A (zh) * 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CN116472046A (zh) * 2020-11-30 2023-07-21 正大天晴药业集团股份有限公司 作为Cdc7抑制剂的盐型及其晶型
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en) 2021-02-08 2022-08-11 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
KR20030034232A (ko) 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
SI1641803T1 (sl) * 2003-06-11 2009-08-31 Xention Ltd Tienopirimidinski derivati kot inhibitorji kalijevih kanalov
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
BRPI0508230A (pt) 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
JP4761389B2 (ja) 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
CN101107253A (zh) 2005-01-19 2008-01-16 默克公司 有丝分裂驱动蛋白抑制剂
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
KR101149954B1 (ko) 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) * 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
KR20110036056A (ko) 2008-06-26 2011-04-06 다나-파버 캔서 인스티튜트 인크. 전이와 관련된 시그너처 및 결정인자 및 이의 사용 방법
US8691828B2 (en) 2009-03-05 2014-04-08 Takeda Pharmaceutical Company Limited Thienopyrimidine as CDC7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011029782A1 (en) 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
ECSP12012160A (es) 2013-03-28
US8921354B2 (en) 2014-12-30
PL2540728T3 (pl) 2019-09-30
JPWO2011102399A1 (ja) 2013-06-17
DK2540728T3 (da) 2019-05-13
EP3533797B1 (en) 2023-12-20
CA2790284A1 (en) 2011-08-25
MA34064B1 (fr) 2013-03-05
AU2011216404A1 (en) 2012-09-20
IL221442A0 (en) 2012-10-31
CY1121792T1 (el) 2020-07-31
SG183304A1 (en) 2012-09-27
MX353500B (es) 2018-01-16
EA201290800A1 (ru) 2013-03-29
EP2540728A1 (en) 2013-01-02
CO6592104A2 (es) 2013-01-02
CA2790284C (en) 2019-01-08
TN2012000401A1 (en) 2014-01-30
US9655900B2 (en) 2017-05-23
BR112012020311B1 (pt) 2019-01-29
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
CN102844320A (zh) 2012-12-26
CL2012002250A1 (es) 2013-02-08
KR20130001246A (ko) 2013-01-03
AU2011216404B2 (en) 2016-04-07
US9388195B2 (en) 2016-07-12
MY164776A (en) 2018-01-30
EP2540728B1 (en) 2019-04-10
CR20120448A (es) 2012-11-13
US20170209452A1 (en) 2017-07-27
MX2012009602A (es) 2012-12-17
US20140228352A1 (en) 2014-08-14
RS58796B1 (sr) 2019-07-31
GEP20146202B (en) 2014-11-25
WO2011102399A1 (ja) 2011-08-25
SI2540728T1 (sl) 2019-06-28
NZ602089A (en) 2014-05-30
HUE043514T2 (hu) 2019-08-28
JP5689454B2 (ja) 2015-03-25
US20150158882A1 (en) 2015-06-11
EP2540728A4 (en) 2013-11-06
PE20130184A1 (es) 2013-03-09
EA020724B1 (ru) 2015-01-30
US20140235615A1 (en) 2014-08-21
CN102844320B (zh) 2016-03-23
US20160310494A1 (en) 2016-10-27
PT2540728T (pt) 2019-07-11
LT2540728T (lt) 2019-06-25
ME03410B (me) 2020-01-20
HRP20190947T1 (hr) 2019-07-26
US8722660B2 (en) 2014-05-13
US8933069B2 (en) 2015-01-13
KR101735868B1 (ko) 2017-05-15
US20130029969A1 (en) 2013-01-31
DOP2012000224A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
BR112012020311A2 (pt) "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto."
BR112015020650A2 (pt) inibidores de histona demetilases
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
JO2848B1 (en) Organic compounds
PH12016502355A1 (en) Pharmaceutical composition
AR092661A1 (es) Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1)
BR112013002250A2 (pt) composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
BR112013006594A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112012022243A2 (pt) terapias inibidoras de autografia baseadas em tioxantona para tratar câncer
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
MX351555B (es) Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.
BR112015020222A2 (pt) compostos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2011, OBSERVADAS AS CONDICOES LEGAIS.